Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xun Lin

Showing results (181-190 of 210) with videos related to

Pageof 21
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2018
Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant SunitinibBrian I Rini, Bernard Escudier, Jean-Francois Martini, et al.
European Urology Oncology|September 29, 2019
Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell CarcinomaAly-Khan A Lalani, Wanling Xie, David A Braun, et al.
Mucosal Immunology|October 16, 2020
IL-22 receptor signaling in Paneth cells is critical for their maturation, microbiota colonization, Th17-related immune responses, and anti-Salmonella immunityStephen J Gaudino, Michael Beaupre, Xun Lin, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 2, 2021
Nrf2 through Aryl Hydrocarbon Receptor Regulates IL-22 Response in CD4<sup>+</sup> T CellsXun Lin, Suzanne Tawch, Hoi Tong Wong, et al.
The New England Journal of Medicine|May 30, 2020
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate CancerCora N Sternberg, Karim Fizazi, Fred Saad, et al.
JCO Global Oncology|February 29, 2020
Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large CohortsDominick Bossé, Wanling Xie, Xun Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 30, 2013
Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trialAlfredo Carrato, Anna Swieboda-Sadlej, Marzanna Staszewska-Skurczynska, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2011
Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinibSandrine Faivre, Magaly Zappa, Valérie Vilgrain, et al.
European Urology|March 1, 2016
Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of EfficacyArnoud J Templeton, Jennifer J Knox, Xun Lin, et al.
Lancet (London, England)|July 19, 2025
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trialKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
Pageof 21

Showing results (181-190 of 210) with videos related to

Sort By:
Pageof 21
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2018
Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant SunitinibBrian I Rini, Bernard Escudier, Jean-Francois Martini, et al.
European Urology Oncology|September 29, 2019
Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell CarcinomaAly-Khan A Lalani, Wanling Xie, David A Braun, et al.
Mucosal Immunology|October 16, 2020
IL-22 receptor signaling in Paneth cells is critical for their maturation, microbiota colonization, Th17-related immune responses, and anti-Salmonella immunityStephen J Gaudino, Michael Beaupre, Xun Lin, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 2, 2021
Nrf2 through Aryl Hydrocarbon Receptor Regulates IL-22 Response in CD4<sup>+</sup> T CellsXun Lin, Suzanne Tawch, Hoi Tong Wong, et al.
The New England Journal of Medicine|May 30, 2020
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate CancerCora N Sternberg, Karim Fizazi, Fred Saad, et al.
JCO Global Oncology|February 29, 2020
Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large CohortsDominick Bossé, Wanling Xie, Xun Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 30, 2013
Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trialAlfredo Carrato, Anna Swieboda-Sadlej, Marzanna Staszewska-Skurczynska, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2011
Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinibSandrine Faivre, Magaly Zappa, Valérie Vilgrain, et al.
European Urology|March 1, 2016
Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of EfficacyArnoud J Templeton, Jennifer J Knox, Xun Lin, et al.
Lancet (London, England)|July 19, 2025
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trialKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
Pageof 21